(S)-HDAC-42

(S)-HDAC-42 is a histone deacetylase (HDAC) inhibitor (IC₅₀ = 16 nM).¹ It increases acetylation of histone H3 in DU145 prostate cancer cells when used at concentrations ranging from 0.1 to 2.5 µM. (S)-HDAC-42 decreases viability of DU145 cells (IC₅₀ = 0.11 µM). It induces cell cycle arrest at the G₁ phase in A2780 ovarian cancer cells when used at a concentration of 0.5 µM.² (S)-HDAC-42 (25 mg/kg per day or 50 mg/kg every other day) decreases tumor volume in a PC3 prostate cancer mouse xenograft model.³

WARNING This product is not for human or veterinary use.

1. Lu, Q., Wang, D.S., Chen, C.S., et al. Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J. Med. Chem. 48(17), 5530-5535 (2005).

2. Yang, Y.-T., Balch, C., Kulp, S.K., et al. A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer. Neoplasia 11(6), 552-563 (2009).

3. Kulp, S.K., Chen, C.S., Wang, D.S., et al. Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer. Clin. Cancer Res. 12(17), 5199-5206 (2006).